Sumitomo Pharma America delivers therapies and pursues clinical advances that improve the lives of people worldwide. We operate with scientific rigor, compassion and determination to address unique and unmet patient needs across oncology, women’s health, urology, rare disease, neurology & psychiatry and cell & gene therapies. For more information on SMPA, visit our website https://www.us.sumitomo-pharma.com or follow us on LinkedIn.
Sumitomo Pharma America (SMPA) is focused on delivering therapeutic and scientific breakthroughs in the areas if critical patient need spanning psychiatry & neurology, oncology, urology, women’s health, rare disease, and cell & gene therapies. The company’s diverse portfolio includes several marketed products and a robust pipeline of early- to late-stage assets.